do peptides FAQ

Combining peptides with SSRIs introduces pharmacokinetic unknowns. SSRIs increase serotonin availability, which indirectly affects BDNF expression. Adding a peptide that directly upregulates BDNF could theoretically produce synergistic effects or could risk overstimulation of neuroplasticity pathways. There's no published data on SSRI-peptide interactions for most compounds. Cerebrolysin has been studied as an adjunct to SSRIs in post-stroke depression trials without significant adverse interactions, but those were medically supervised settings with close monitoring. Self-administering research peptides while on prescription psychiatric medications is high-risk. Serotonin syndrome, though unlikely with non-monoaminergic peptides, isn't the only concern. HPA axis modulation and dopaminergic effects could alter your existing medication's efficacy or side effect profile unpredictably.

Start with a GHRP + GHRH stack (GHRP-2 100mcg + CJC-1295 100mcg) dosed three times daily. Post-workout, before bed, and upon waking. This timing aligns with natural GH pulse windows and training stimulus. Expect subtle improvements in recovery and sleep quality within 2 weeks, measurable body composition changes after 8–10 weeks. If you see no subjective recovery benefit by week 3, you're either under-responding or the peptide quality is insufficient. GH secretagogues produce noticeable sleep architecture improvements even when hypertrophy gains are modest.

Switch to subcutaneous administration or verify peptide purity via third-party testing. Oral bioavailability for most therapeutic peptides is under 5%—enzymatic degradation by pepsin, trypsin, and chymotrypsin in the GI tract cleaves peptide bonds before absorption. Even enteric-coated formulations may not survive the full digestive process intact. BPC-157 administered subcutaneously at 250–500 mcg daily delivers 85–95% bioavailability and reaches therapeutic plasma levels within 30–60 minutes. If symptoms persist after route optimization, the issue may not be barrier permeability alone—consider comprehensive stool testing for dysbiosis, SIBO, or parasitic infection.

BPC-157 occupies a regulatory gray zone: it's not FDA-approved as a drug but is legally available from compounding pharmacies and research peptide suppliers for experimental use. If you're sourcing it for personal research, ensure the supplier provides third-party purity verification (HPLC-MS) showing ≥98% purity—impurities can cause injection site reactions or unpredictable pharmacokinetics. Subcutaneous injection requires sterile technique (alcohol prep, single-use syringes) and proper reconstitution with bacteriostatic water if purchasing lyophilized powder. Store reconstituted peptide at 2–8°C and use within 28 days. Understand that using research peptides outside clinical trial oversight carries risk—there's no formal safety monitoring or adverse event reporting system.

Combining BPC-157 with a growth hormone secretagogue like MK-677 addresses both local and systemic repair pathways simultaneously. BPC-157 targets the injury site directly through vascular and fibroblast mechanisms; MK-677 elevates circulating IGF-1 to support protein synthesis across all recovering tissue. No published studies have tested this combination in rotator cuff models specifically, but the mechanisms don't interfere—one works locally via injection, the other systemically via oral administration. Avoid combining peptides with overlapping mechanisms (e.g., multiple GH secretagogues) unless dose-adjusting to prevent supra-physiological hormone elevation.

Stacking can work if the peptides target different pathways, but redundant mechanisms add cost without benefit. Combining MK 677 (mitochondrial function) with Thymalin (oxygen transport) addresses two distinct bottlenecks. Using two different growth hormone secretagogues simultaneously is redundant. You're stimulating the same pathway twice. Start with a single peptide, measure baseline metrics (VO2 max, time to exhaustion, recovery heart rate), and add a second compound only if the first produces measurable benefit.

MK-677 is a ghrelin mimetic. It directly stimulates the same receptor that triggers hunger. If appetite control is already a challenge, switch to CJC-1295/Ipamorelin, which doesn't activate ghrelin receptors and produces minimal appetite effects. The GH elevation is comparable, but the hunger signal is absent. Appetite regulation is a critical variable in recomposition. If the peptide undermines dietary adherence, the net effect is negative regardless of the hormonal benefit.

Verify peptide purity and storage conditions first. Peptides degrade rapidly when exposed to temperatures above 8°C for extended periods or when reconstituted with non-bacteriostatic water. A degraded peptide loses receptor affinity without changing appearance. Lab testing via HPLC is the only way to confirm integrity. Second, assess whether the peptide mechanism matches the injury stage. Using a collagen-remodeling peptide (GHK-Cu) during the inflammatory phase (days 1–3) produces minimal effect because collagen deposition hasn't started yet. Timing peptide administration to the proliferative phase (days 4–14) yields 2–3× the benefit.

Selank is not FDA-approved in the United States and is classified as a research compound. It is legally available from research chemical suppliers for investigational use only. Not for human consumption. Clinical use requires importation under physician oversight or participation in a research protocol. Our team consistently advises that research-grade peptides like Selank should be obtained through verified suppliers with third-party purity testing, not through unregulated nootropic vendors. Contamination, incorrect dosing, and mislabeling are common in unverified peptide products.

Peptide response timelines differ from conventional drugs. Biologics often require 8–12 weeks to show effect; peptides targeting mucosal repair may need similar durations. However, if zero symptom change occurs after four weeks on properly dosed subcutaneous BPC-157 or enema-delivered KPV, the compound is either not reaching target tissue or the dominant IBD mechanism in your case isn't responsive to that peptide's pathway. KPV works best when NF-κB is the primary driver; if your inflammation is IL-23-mediated or driven by adaptive immunity, KPV won't address it.

Start GHK-Cu within the first week of wound closure to modulate collagen remodeling before excessive fibrosis begins. Keloid formation is driven by prolonged TGF-β (transforming growth factor-beta) signaling—GHK-Cu reduces TGF-β expression by upregulating decorin, a proteoglycan that binds and inactivates TGF-β. Apply twice daily for 8–12 weeks. Silicone sheeting combined with GHK-Cu shows additive benefit in clinical studies.

If the vial was unreconstituted (still in lyophilized powder form), brief temperature excursions up to 25°C for 12–24 hours typically don't cause complete degradation. Though potency may drop by 10–20%. If the vial was already reconstituted with bacteriostatic water and left above 8°C for more than 4 hours, the peptide structure is likely denatured. Peptides are proteins, and proteins unfold irreversibly at elevated temperatures. There's no home test to verify potency. Discard it and reconstitute a fresh vial.

Maintenance dosing may support collagen maturation during the remodeling phase. TB-500 research protocols include a maintenance phase of 5 milligrams monthly for 3–6 months after initial healing. This continues to support collagen crosslinking as tensile strength gradually returns to baseline. Without adequate remodeling time (typically 6–12 months), re-injury rates remain elevated because collagen fibers lack proper alignment and crosslinking density.

You will see improved lean mass retention and potentially improved insulin sensitivity, but visceral fat will not meaningfully decrease without a caloric deficit. Growth hormone secretagogues activate hormone-sensitive lipase. The enzyme that breaks down stored fat. But if you're consuming more energy than you expend, new triglycerides are stored faster than old ones are mobilized. The peptides create a better hormonal environment, but fat loss still requires energy expenditure to exceed intake.

If you've maintained a documented deficit (tracked intake, stable weight for 4+ weeks) and waist circumference hasn't changed, metabolic adaptation has likely reduced your expenditure to match intake. You're no longer in deficit. Growth hormone declines during prolonged restriction, and cortisol rises. Both shifts favor visceral fat retention. Introducing a growth hormone secretagogue can restart mobilization by re-elevating GH levels and reducing local cortisol production in abdominal adipose tissue. Pair it with a diet break (2 weeks at maintenance calories) to reset leptin and thyroid hormone before resuming deficit.

Peptides aren't stimulants—you won't 'feel' them working the way you might notice caffeine or a probiotic shift. BPC-157's mechanism (angiogenesis, tight junction repair) operates at the cellular level over weeks, not days. Objective markers like reduced bowel movement urgency, normalized stool consistency, or decreased systemic inflammation (measured via hsCRP or fecal calprotectin) are more reliable indicators than subjective symptom tracking. If no objective improvement appears after 6–8 weeks at therapeutic dose, the intervention may not be addressing your specific pathology.

Combining peptides with controlled mechanical loading is the ideal protocol. Physical therapy applies stress to healing tissue, which signals collagen fibers to align along the direction of force. This is how ligaments regain tensile strength. Peptides accelerate the biological repair processes, but they don't replace the mechanical stimulus ligaments need to remodel correctly. Think of peptides as accelerating the material supply, and physical therapy as directing the construction.

No pharmacokinetic interactions have been reported between BPC-157 and KPV. They act through distinct pathways (growth factor signaling vs NF-kB inhibition). Researchers often combine them in IBD models to address both inflammation and barrier repair simultaneously. Standard protocol: KPV 500 mcg oral twice daily + BPC-157 250 mcg subcutaneous once daily. Monitor for additive gastrointestinal effects (rare, but increased motility has been observed in sensitive individuals). The combination targets complementary mechanisms without redundancy.

Switch peptides. Cerebrolysin targets neuroplasticity and acetylcholine synthesis, which won't help if your brain fog is driven by mitochondrial insufficiency or systemic inflammation. Consider Cartalax or MK 677 for mitochondrial support, or Thymalin if post-viral immune activation is the root cause. Brain fog from different mechanisms requires different peptides. Using the wrong one produces zero improvement regardless of dose or duration.

Switch to intranasal administration or use a lipophilic analog. The blood-brain barrier excludes hydrophilic peptides >500 Da via tight junction restriction. Cerebrolysin and P21 both fall into this category when administered systemically. Intranasal delivery bypasses the BBB by transporting peptides along olfactory and trigeminal nerve pathways directly into the CSF and brain parenchyma. In olfactory bulbectomy models, intranasally delivered P21 reached hippocampal concentrations 8× higher than intraperitoneal injection at equivalent doses (Drug Deliv, 2017). Alternatively, lipophilic modifications (like dihexa's N-hexanoic acid tail) increase passive membrane permeability. But chemical modification can alter receptor binding specificity.